PDF(Pubmed)
Abstract：
Infection-induced SARS-CoV-2 seroprevalence has been studied worldwide. At Juntendo University Hospital (JUH) in Tokyo, Japan, we have consistently conducted serological studies using the blood residue of healthcare workers (HCWs) at annual health examinations since 2020. In this 2023 study (n = 3,594), N-specific seroprevalence (infection-induced) was examined while univariate and multivariate logistic regression analyses were performed to compute ORs of seroprevalence with respect to basic characteristics of participants. We found that the N-specific seroprevalence in 2023 was 54.1%-a jump from 17.7% in 2022, and 1.6% in 2021-with 37.9% as non-PCR-confirmed asymptomatic infection cases. Those younger than 50 (adjusted OR = 1.62; p < .001) and recipients with 4 doses or less of vaccine had a higher risk to be N-positive, ranging from 1.45 times higher for the participants with 4 doses (p < .001) to 4.31 times higher for the participants with 1 dose (p < .001), compared to those with 5 or more doses. Our findings indicate that robust vaccination programs may have helped alleviate symptoms but consequently caused asymptomatic spread in this hospital, especially among younger HCWs. Although having four doses or less was found to be associated with higher risk of infection, the optimal constitution and intervals for effective booster vaccines warrant further investigations.
摘要：
感染引起的SARS-CoV-2血清阳性率已在世界范围内进行了研究。在东京的Juntendo大学医院（JUH），Japan,自2020年以来,我们一直在每年的健康检查中使用医护人员(HCWs)的血液残留进行血清学研究.在这项2023年的研究中（n=3,594），检查了N特异性血清阳性率（感染引起的），同时进行了单变量和多变量逻辑回归分析，以根据参与者的基本特征计算血清阳性率的OR。我们发现，2023年的N特异性血清阳性率为54.1％-比2022年的17.7％和2021年的1.6％-非PCR确认的无症状感染病例为37.9％。年龄小于50岁的患者（校正后的OR=1.62；p<.001）和接种4剂或更少的疫苗的接种者N阳性的风险更高，范围从1.45倍高的参与者与4剂量（p<.001）为4.31倍高的参与者与1剂量（p<.001），与5个或更多剂量的人相比。我们的研究结果表明，强大的疫苗接种计划可能有助于缓解症状，但因此导致无症状传播在这家医院，尤其是年轻的HCWs。尽管发现四个或更少的剂量与更高的感染风险有关，有效加强疫苗的最佳构成和间隔值得进一步研究。
